Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Centogene N.V. (CNTG)

Centogene N.V. (CNTG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,804
  • Shares Outstanding, K 19,860
  • Annual Sales, $ 224,700 K
  • Annual Income, $ -55,430 K
  • 60-Month Beta -1.17
  • Price/Sales 0.16
  • Price/Cash Flow N/A
  • Price/Book 0.68
Trade CNTG with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +17.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3400 +11.94%
on 07/28/22
2.4800 -39.52%
on 07/14/22
-0.7800 (-34.21%)
since 07/08/22
3-Month
1.3400 +11.94%
on 07/28/22
3.4600 -56.65%
on 05/17/22
-1.7200 (-53.42%)
since 05/10/22
52-Week
1.3400 +11.94%
on 07/28/22
11.5500 -87.01%
on 08/16/21
-9.9100 (-86.85%)
since 08/10/21

Most Recent Stories

More News
Azenta (AZTA) Q3 Earnings Beat Estimates

Brooks (AZTA) delivered earnings and revenue surprises of 50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AZTA : 63.01 (-1.32%)
CNTG : 1.4700 (+5.00%)
Clover Health Investments, Corp. (CLOV) Reports Q2 Loss, Lags Revenue Estimates

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 4.35% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the...

CLOV : 2.97 (+6.45%)
CNTG : 1.4700 (+5.00%)
CENTOGENE Reports First Quarter 2022 Financial Results

On Track for FY 2022 Guidance Q1 2022 revenue rises 3% to €10.3 million Completed phase out of COVID-19 Business segment in Q1 2022Positioning Pharma and...

CNTG : 1.4700 (+5.00%)
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential...

CNTG : 1.4700 (+5.00%)
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO...

CNTG : 1.4700 (+5.00%)
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential...

CNTG : 1.4700 (+5.00%)
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO...

CNTG : 1.4700 (+5.00%)
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18...

CNTG : 1.4700 (+5.00%)
AGIO : 27.52 (+0.55%)
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates

Phreesia (PHR) delivered earnings and revenue surprises of 9.17% and 1.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

PHR : 25.30 (+6.66%)
CNTG : 1.4700 (+5.00%)
Change Healthcare (CHNG) Q4 Earnings Miss Estimates

Change Healthcare (CHNG) delivered earnings and revenue surprises of -9.30% and 1.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CHNG : 24.42 (+0.41%)
CNTG : 1.4700 (+5.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company's goal is to bring rationality to treatment decisions and to accelerate the development...

See More

Key Turning Points

3rd Resistance Point 1.7168
2nd Resistance Point 1.6535
1st Resistance Point 1.5267
Last Price 1.4700
1st Support Level 1.3366
2nd Support Level 1.2733
3rd Support Level 1.1465

See More

52-Week High 11.5500
Fibonacci 61.8% 7.6498
Fibonacci 50% 6.4450
Fibonacci 38.2% 5.2402
Last Price 1.4700
52-Week Low 1.3400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar